Du är här

2014-04-11

MorphoSys AG: Announcement of the Convening of the AGM in Munich/Germany on 23 May 2014 according to sec. 121 para. 4a AktG with the objective of Europe-wide d

MorphoSys AG / MorphoSys AG: Announcement of the Convening of the AGM in
Munich/Germany on 23May 2014 according to sec. 121 para. 4a AktG with the
objective of Europe-wide distribution. Processed and transmitted by NASDAQ
OMX Corporate Solutions. The issuer is solely responsible for the content of
this announcement.
MorphoSys AG

Martinsried/Planegg
Securities Code Number: 663200
ISIN: DE0006632003

Convenience Translation:

The text decisive for the invitation to the Annual General Meeting of
MorphoSys AG is the one written in the German language.

Invitation to the Annual General Meeting 2014 of MorphoSys AGWe hereby invite the shareholders of our Company to the Annual General Meeting
which is taking place on Friday, 23 May 2014 at 10:00 a.m., in the Conference
Center Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich.
Agenda
1 Presentation of the adopted financial statements and the approved
consolidated financial statements as of 31 December 2013, the management
reports including the report of the Supervisory Board for the 2013
financial year and the explanatory report of the Management Board regarding
the disclosures pursuant to section 289 para. 4, 315 para. 4 German
Commercial Code (HGB )
2 Resolution on the use of the accumulated profit of MorphoSys AG for the
2013 financial year
3 Resolution on the formal approval of the activities of the members of the
Management Board in respect of the 2013 financial year
4 Resolution on the formal approval of the activities of the members of the
Supervisory Board in respect of the 2013 financial year
5 Resolution on the appointment of the auditor for the 2014 financial year
6 Resolution on the cancellation of the Conditional Capital 1999-I and the
Conditional Capital 2008/II as well as the reduction of Conditional Capital
2003-II; amendments of the Articles of Association
7 Resolution on the creation of a new Authorized Capital 2014-I with the
possibility to exclude pre-emptive rights of the shareholders; amendment of
the Articles of Association
8 Resolution on the election of a Supervisory Board member
9 Resolution regarding the authorization to purchase treasury shares pursuant
to Section 71 para. 1 no. 8 of the German Stock Corporation Act and to use
treasury shares with the possibility to exclude pre-emptive rights of the
shareholders
10 Resolution regarding the remuneration of the Supervisory Board

Please find the full text of the invitation here:www.morphosys.com/agmAbout MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
therapeuticpipelineof more than 80 human antibody drug candidates for the
treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name
just a few. With its ongoing commitment to new antibody technology and drug
development, MorphoSys is focused on making the healthcare products of
tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the
symbol MOR. For regular updates about MorphoSys,
visithttp://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®
and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties. Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated. MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Mario Brkulj
Associate Director Corporate Communications&IR

Alexandra Goller
Specialist Corporate Communications&IR

Jessica Rush
Specialist Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1775599

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.